Trident Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.50 M
as on 22-06-2024
- Paid Up Capital ₹ 4.50 M
as on 22-06-2024
- Company Age 35 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.20 Cr
as on 22-06-2024
- Satisfied Charges ₹ 1.00 Cr
as on 22-06-2024
- Revenue -3.14%
(FY 2020)
- Profit 98.88%
(FY 2020)
- Ebitda 167.15%
(FY 2020)
- Net Worth -0.10%
(FY 2020)
- Total Assets -0.22%
(FY 2020)
About Trident Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.50 M and a paid-up capital of Rs 4.50 M.
The company currently has active open charges totaling ₹1.20 Cr. The company has closed loans amounting to ₹1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sai Chepuri and Chepuri Sai serve as directors at the Company.
- CIN/LLPIN
U24230TG1989PTC010577
- Company No.
010577
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Oct 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- LocationAndhra Pradesh, Telangana
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Trident Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sai Chepuri  | Additional Director | 17-Feb-2017 | Current |
| Chepuri Sai | Additional Director | 17-Feb-2017 | Current |
Financial Performance of Trident Pharmaceuticals.
Trident Pharmaceuticals Pvt Ltd, for the financial year ended 2020, experienced Minor drop in revenue, with a 3.14% decrease. The company also saw a substantial improvement in profitability, with a 98.88% increase in profit. The company's net worth dipped by a decrease of 0.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Trident Pharmaceuticals?
In 2019, Trident Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Karur Vysya Bank Limited Creation Date: 25 Sep 2014 | ₹2.00 M | Open |
Ing Vysya Bank Limited Creation Date: 01 Sep 2006 | ₹2.00 M | Open |
Ing Vysya Bank Limited Creation Date: 29 Sep 2005 | ₹8.00 M | Open |
How Many Employees Work at Trident Pharmaceuticals?
Unlock and access historical data on people associated with Trident Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Trident Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Trident Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
